Literature DB >> 31166129

Cigarette and ENDS preparations differentially regulate ion channels and mucociliary clearance in primary normal human bronchial 3D cultures.

Rachael E Rayner1, Patrudu Makena2, Gaddamanugu L Prasad2, Estelle Cormet-Boyaka1.   

Abstract

Cigarette smoking is known to disrupt the normal mucociliary function of the lungs, whereas the effect of electronic nicotine delivery systems (ENDS) is not completely understood. This study aimed to compare the effects of acute exposure of primary normal human bronchial epithelial (NHBE) 3D cultures at air-liquid interface to combustible cigarette and ENDS preparations on mucociliary function, including ion channel function, ciliary beat frequency (CBF), and airway surface liquid (ASL) height. Differentiated NHBE cultures were exposed to whole smoke-conditioned media (WS-CM) or total particulate matter (TPM) prepared from 3R4F reference cigarettes, whole aerosol-conditioned media (ACM) or e-TPM generated from a marketed ENDS product, or nicotine alone. We found that a dose of 7 μg/mL equi-nicotine units of cigarette TPM and WS-CM significantly decreased cystic fibrosis transmembrane conductance regulator (CFTR) and the epithelial sodium channel (ENaC) function, which regulates fluid homeostasis in the lung. Conversely, higher (56 µg/mL) equi-nicotine units of ENDS preparations or nicotine alone had no effect on CFTR and ENaC function. Despite a significant decrease in ion channel function, cigarette smoke preparations did not alter CBF and ASL. Similarly, ENDS preparations and nicotine alone had no effect on ASL and CBF. This study demonstrates that acute exposures of cigarette smoke preparations exert a notable inhibitory effect on CFTR and ENaC function compared with ENDS preparations. In summary, the functional assays described herein are potentially useful for tobacco product evaluations.

Entities:  

Keywords:  ENDS preparations; ion channels; mucociliary clearance; primary normal human bronchial epithelial (NHBE) cells; tobacco preparations

Mesh:

Substances:

Year:  2019        PMID: 31166129     DOI: 10.1152/ajplung.00096.2019

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  6 in total

Review 1.  What are the respiratory effects of e-cigarettes?

Authors:  Jeffrey E Gotts; Sven-Eric Jordt; Rob McConnell; Robert Tarran
Journal:  BMJ       Date:  2019-09-30

2.  Differential gene expression of 3D primary human airway cultures exposed to cigarette smoke and electronic nicotine delivery system (ENDS) preparations.

Authors:  Rachael E Rayner; Patrudu Makena; Gang Liu; G L Prasad; Estelle Cormet-Boyaka
Journal:  BMC Med Genomics       Date:  2022-04-03       Impact factor: 3.622

3.  E-cigarette exposures, respiratory tract infections, and impaired innate immunity: a narrative review.

Authors:  Aleks Kalininskiy; Julie Kittel; Nicholas E Nacca; Ravi S Misra; Daniel P Croft; Matthew D McGraw
Journal:  Pediatr Med       Date:  2021-02-28

4.  Multi-endpoint analysis of human 3D airway epithelium following repeated exposure to whole electronic vapor product aerosol or cigarette smoke.

Authors:  Lukasz Czekala; Roman Wieczorek; Liam Simms; Fan Yu; Jessica Budde; Edgar Trelles Sticken; Kathryn Rudd; Thomas Verron; Oleg Brinster; Matthew Stevenson; Tanvir Walele
Journal:  Curr Res Toxicol       Date:  2021-02-20

Review 5.  A Summary of In Vitro and In Vivo Studies Evaluating the Impact of E-Cigarette Exposure on Living Organisms and the Environment.

Authors:  Anna Merecz-Sadowska; Przemyslaw Sitarek; Hanna Zielinska-Blizniewska; Katarzyna Malinowska; Karolina Zajdel; Lukasz Zakonnik; Radoslaw Zajdel
Journal:  Int J Mol Sci       Date:  2020-01-19       Impact factor: 5.923

Review 6.  Collecting e-cigarette aerosols for in vitro applications: A survey of the biomedical literature and opportunities to increase the value of submerged cell culture-based assessments.

Authors:  Daniel J Smart; Gary Phillips
Journal:  J Appl Toxicol       Date:  2020-10-04       Impact factor: 3.446

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.